摘要
目的探讨拉米夫定治疗是否会影响慢性乙型肝炎患者 (CHB) HBV特异性细胞毒 T淋巴细胞 (CTL)活性。方法选择 34例 HL A- A2 +CHB患者 ,其中 19例患者行干扰素 - α治疗 ,另 15例患者用拉米夫定治疗。在治疗前和治疗后 1、3、6个月后分离外周血单核细胞 (PBMC) ,经体外诱导扩增 ,以 Hep G2 .2 .15细胞和 Hep G2细胞作靶细胞 ,乳酸脱氢酶释放法检测其细胞毒活性。结果在接受干扰素 - α或拉米夫定治疗后 ,CHB患者 HBV特异性 CTL 活性均能得到不同程度的恢复。两种治疗方法比较显示 ,干扰素 - α治疗组 CTL 活性增强持续的时间较使用拉米夫定的治疗组长。结论拉米夫定治疗能短暂地增强 CHB患者 HBV特异性 CTL 活性。
ObjectiveTo study whether anti viral treatment by lamivudine can reconstitute CTL responses in CHB patients Methods PBMCs were separated routinely during lamivudine or interferon α treatment,and stimulated by peptide HBcAg18 27/rHBcAg/rIL 2.The cytotoxic activities against HBV DNA transfected hepatoma cells(2 2 15) and HepG2 cells were detected by lactate dehydrogenase(LDH) assay after 21 days cultivation Results The cytotoxic activities against HepG2 2 15 cells increased significantly by whether lamivudine or interferon α treatment which have not obviously effect on the cytotoxic activities against HepG2 cells The increased HBV specific CTL activities by interferon α treatment lasted longer than lamivudine treatment Conclusion Treatment with lamivudine could restore HBV specific CTL activities partly and transiently but could not eliminate HBV persistently
出处
《免疫学杂志》
CAS
CSCD
北大核心
2001年第6期460-462,481,共4页
Immunological Journal
